The use of PPAR-γ agonists is associated with effective improvement in cognitive function.

A systematic review and meta-analysis aimed to critically analyze and investigate the existing data on the effects of peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist therapy on the cognitive status of patients.

Electronic databases such as EMBASE, PubMed, Web of Science, and Elsevier were investigated for relevant literature searches. Depending on the illness state, analysis of both early and later therapy with PPAR-γ agonist was done. Stata (version 12) was utilized to abstract and analyze the data in order to procure more comprehensive results.

According to the research, high-dose PPAR-γ medication may have a better therapeutic outcome, particularly in reversing the impact of cognitive decline. Early PPAR-γ agonist intervention is advantageous for patients and have a protective effect against dementia in people who are taking them for diabetes management.

Pioglitazone's effectiveness appears to be promising, especially for individuals with concomitant diabetes. When compared to Rosiglitazone, Pioglitazone showed a greater clinical curative efficacy and level of safety.

Hence, PPAR-γ agonists have a significant role in the inflammatory response of Alzheimer's disease and diabetes mellitus patients. Clinical therapies should put more emphasis on pertinent metabolic indicators.